---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-058956"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T05:16:19.728035+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CG Oncology reports 42.3% 24-month CR rate in BOND-003; 97.3% progression-free at 24 mo

## Summary
- BOND-003 Cohort C: 75.5% complete response (CR) at any time; 42.3% 24-month CR by K-M estimate.
- Median duration of response 28 months; 58.3% of responders maintained CR at 24 months by K-M.
- 97.3% of patients free from progression to muscle-invasive bladder cancer at 24 months; 91.6% cystectomy-free.
- No Grade 3+ treatment-related adverse events or deaths; median resolution of any TRAE was one day.
- Cohort P (Ta/T1 without CIS): 90.5% high-grade recurrence-free survival at 3 and 9 months (n=24).

## SEC filing metadata
- accession: 0000950170-25-058956
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000095017025058956/0000950170-25-058956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000095017025058956/ck0001991792-20250426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-058956
- JSON: https://secwatch.observer/filing/0000950170-25-058956.json
- Plain text: https://secwatch.observer/filing/0000950170-25-058956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.